Back to search results

Investigating Semaglutide for Muscle and Bone Health in Older Women with Type 2 Diabetes

This study is looking at how a common diabetes medication, Semaglutide (a GLP-1 RA therapy), affects muscle and bone health in women aged 65 or older who have type 2 diabetes. Researchers want to see if 6 months of Semaglutide treatment changes muscle strength, specifically handgrip strength. You might be able to join if you are a postmenopausal woman over 65 with type 2 diabetes, a BMI between 27 and 40, and an A1c between 7-10%. The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
What's involved
You would receive Semaglutide, have muscle strength tests (hand grip, Timed Up and Go), provide blood samples, and undergo bone mineral density testing. The main muscle strength assessment will be measured at Baseline, week 4, week 8, week 12, and week 26.
Compensation
Not stated in the trial record.
Follow-up
Muscle strength will be measured at Baseline, week 4, week 8, week 12, and week 26.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07428746

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Recruiting
PHASE3Ages 65+InterventionalTreatment
Emory University
~20 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:Semaglutide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in handgrip strength
Measured over Baseline, week4, week 8, week12, week 26.

Conditions

Diabetes Mellitus, Type 2

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Thaer Idrees, MD, FSSCI · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Thaer Idrees, MD, FSSCI
[email protected]
404-251-5357
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal women aged 65 years or older
Has type 2 diabetes
Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
Hemoglobin A1c \>7% within 3 months of the first visit.
Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
No osteoporosis confirmed on DEXA scan within 12 months
Able to provide informed consent and participate in all study assessments

Exclusion

Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
eGFR \<30 ml/min in the last 3 months
Patients with a history of treatment with anti-osteoporosis agents
Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
Documented presence of prosthesis or devices in the spine or hip
Previous fragility fracture
Males
Moderate to severe gastroesophageal reflux disease based on patient history.
Inability to comply with the treatment protocol or to understand the consent form.
Aspartate aminotransferase (AST) \> 3 times normal or alanine aminotransferase (ALT) \> 3 times the normal
Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.
Personal or family history of medullary thyroid carcinoma.
Personal or family history of multiple endocrine neoplasia type 2 syndrome.
Personal history of gastroparesis, celiac disease, hypogonadism, severe COPD, hypopituitarism, or Cushing's disease
Personal history of severe diabetic retinopathy.
Known serious hypersensitivity, including anaphylaxis and angioedema, to semaglutide or any of its excipients.
Any of the following drugs or treatments were used within 6 months before screening: treated with GLP-1RA, GIP analogues, pioglitazones
Concomitant treatment with GLP-1 receptor agonist therapy
Long-term intravenous, oral, and intra-articular administration of high-dose corticosteroids within 2 months before screening (more than 7 days in a row)
Use of weight control drugs or surgery that can lead to weight changes during the last 6 months before screening, or are currently in the weight loss plan and are not in the maintenance stage
Incarcerated individuals

What this trial measures

  • Change in handgrip strengthBaseline, week4, week 8, week12, week 26.

    Handgrip strength is a validated indicator of overall muscle strength and a core diagnostic component of sarcopenia. HGS will be assessed using a calibrated hydraulic hand dynamometer. Output is recorded in kilograms (kg) of force. Higher values indicate greater muscle strength